肠道微生物群在风湿性疾病发展中的作用：以纤维肌痛为重点
The role of the gut microbiota in the development of rheumatic diseases: a focus on fibromyalgia.
摘要(中文译文)
纤维肌痛（FM）是一种慢性广泛性疼痛综合征，影响2%~4%的人口，其病理生理机制仍未完全阐明。越来越多的证据表明，肠道菌群失调是其中一个促发因素，通过免疫、神经内分泌和代谢途径发挥作用，并可能强化中枢敏化。微生物多样性降低及代谢物谱改变——包括短链脂肪酸、胆汁酸和色氨酸衍生物——的一致发现提示肠道与FM症状之间存在机制性联系。以微生物群为靶点的干预措施，如益生菌、饮食调整和粪菌移植，已显示出初步获益，但证据仍受样本量小和方法学异质性的限制。本综述在风湿性疾病的更广泛背景下，综合了目前关于肠道微生物群在FM中作用的认识，并讨论了未来的研究方向。
Abstract
Fibromyalgia (FM) is a chronic widespread pain syndrome affecting 2%-4% of the population whose pathophysiology remains incompletely understood. Growing evidence implicates gut microbiota dysbiosis as a contributing factor, acting through immune, neuroendocrine, and metabolic pathways that may reinforce central sensitization. Consistent findings of reduced microbial diversity and altered metabolite profiles-including short-chain fatty acids, bile acids, and tryptophan derivatives-suggest mechanistic links between the gut and FM symptoms. Microbiota-targeted interventions such as probiotics, dietary modification, and fecal microbiota transplantation have shown preliminary benefits, though evidence remains limited by small sample sizes and methodological heterogeneity. This review synthesizes current knowledge on the role of the gut microbiota in FM within the broader context of rheumatic diseases and discusses future research directions.
如何引用
AMA
Yongli Zhao, Xingwen Xie. The role of the gut microbiota in the development of rheumatic diseases: a focus on fibromyalgia.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1845199.
APA
Yongli Zhao, Xingwen Xie (2026). The role of the gut microbiota in the development of rheumatic diseases: a focus on fibromyalgia.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1845199
GB/T 7714
Yongli Zhao, Xingwen Xie. The role of the gut microbiota in the development of rheumatic diseases: a focus on fibromyalgia.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1845199.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出